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The last four decades have seen spectacular 
developments in the management of pulmonary 
tuberculosis. The discovery of streptomycin in 
1943 by Waksman was soon followed by other 
drugs with anti-tuberculosis activity, such as 
PAS, isoniazid, pyrazinamide, thioacetazone, 
ethambutol, rifampicin and others. The dis-
covery of the anti-tuberculosis activity of isonia-
zid in 1952 was a great land-mark which re-
volutionalised the treatment of tuberculosis. 
Because of its high efficacy, low toxicity and low 
cost, isoniazid soon became the drug of choice in 
tuberculosis. Administered alone daily for 12 
months, it has a potential of producing bacteri-
ological quiescence in approximately 70% of 
pulmonary tuberculosis cases excreting isoniazid-
sensitive cultures in their sputum. The con-
comitant administration of thioacetazone or 
PAS daily for 1 year increases the efficacy of the 
regimen to about 85%. However, approxima-
tely 20% of the patients with quiescent disease 
at 1 year have a bacteriological relapse after 
stopping chemotherapy, so that the overall 
efficacy of the 2-drug regimens is reduced to 
less than 70% even among those patients who 
consume the drugs regularly. Such relapses 
can be prevented by continuing chemotherapy 
beyond 12 months for another 6-12 months. It 
is, therefore, customary to prescribe regimens 
of ! 8-24 months to tuberculosis patients. 
The routine application of the conventional 
regimens in tuberculosis control programmes 
has been found to be difficult. Many patients 
become irregular in taking treatment as the 
months advance; indeed, over half the patients 
discontinue treatment by 12 months, and very 
few complete the prescribed 18 to 24 months of 
treatment. Regularity of treatment, however, is 
generally high in the early months of treatment. 
This factor has provided the basis for develop-
ing effective regimens which produce rapid 
sputum conversion, so that they need be admi-
nistered for durations considerably shorter 
than the conventional 12-24 months. The dis-
covery of rifampicin, a bactericidal drug with 
activity matching that of isoniazid, provided the 
necessary stimulus for evolving short-course 
regimens. 
The first report of effective short-course re-
gimens came from Hast Africa.1,2 In this study, 
he efficacy of four 6-month regimens in pulmo- t  
nary tuberculosis was investigated in comparison 
with a standard daily regimen of thioacetazone 
plus isoniazid for 18 months. It was found that 
the 3-drug combination of streptomycin plus iso-
niazid plus rifampicin—SHR—caused sputum 
conversion in 100% by the end of 6 months; 
further:, these patients continued “to have quies-
cent disease even after stopping chemotherapy, 
with only 2% having a relapse by the end of 5 
years. This study was the forerunner of several 
other studies in East Africa and other countries, 
including India. 
The success of short-course regimens 
depends upon a proper choice of drugs which 
have bactericidal as well as sterilising activity. 
Evidence regarding bactericidal activity can be 
obtained from laboratory studies on the effect 
of the drugs on cultures of tubercle bacilli in 
vitro, efficacy of the drugs in experimental tuber-
culosis in laboratory animals, the speed of 
sputum conversion in patients undergoing 
treatment and the magnitude of the fall in the 
bacterial content of sputum within a short 
period of initiation of chemotherapy. The steri-
lising activity of drugs is assessed from the pro-
portion of patients who have bacteriological 
relapses after stopping chemotherapy. 
Isoniazid, rifampicin, streptomycin and pyra-
zinamide are drugs which exert bactericidal 
activity and Table I summarises their relative 
bactericidal properties as assessed by their 
activities in laboratory studies in vitro and 
against experimental tuberculosis in animals. 
Isoniazid and rifampicin have the highest bacte-
ricidal activity, while streptomycin and pyrazi-
namide are relatively less active. The evidence 
in man, however, is indirect. Ethical consider-
ations prevent the study of single-drug regimens 
in clinical practice with the object of determin-
ing the relative efficacies of individual drugs. 
We have, however, a wealth of information on 
the relative efficacy of combinations of these 
drugs from carefully conducted controlled trials 
in man, and it has been possible to apportion 
the contribution of individual drugs to the over-
all efficacy of regimens. The clinical results are 
generally in conformity with the laboratory 
findings and, together, they provide the scientific 
basis for formulating short-course regimens for 
tuberculosis control programmes. 
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bactericidal activity of the regimen is small. In 
contrast, the addition of pyrazinamide or rifa-
mpicin contributes significantly to the bacteri-
cidal activity. Thus, the clinical evidence 
suggests that isoniazid, rifampicin and pyrazi-
namide are drugs which kill the bacilli and are 
therefore suitable for short-course chemothe-
rapy. Bacteriostatic drugs such as thiacetazone, 
PAS or ethambutol are unlikely to make sign-
ficant contribution to the activity of short-
course regimens. The contribution of strepto-
mycin also would appear to be small. Further 
evidence on the activity of the drugs is derived 
from the findings on bacteriological relapse. 
Examples of sterilising activities of different 
drug combinations in man are presented in 
Table 3. 
It is clear that the addition of thioacetazone 
to SH did not contribute to the sterilising acti-
vity of the regimen and the relapse rate continu-
ed to be high, namely, 22%; pyrazinamide, on 
 
TABLE 1 
Bactericidal activity of main antituberculosis drugs 
TABLE 2 
Bactericidal activity of daily regimens in 
Sputum-positive patients 
Regimen           Percent culture-negative
   at   2 months 
 
      H    44 
 
      TH    44 
 
       PH    42 
 
       EH    49 
 
        
        SH    49 
 
        STH   42 
 
        SHZ   66 
 
        HR    64 
 
        SHR   70 
 
        SHRZ   95 
 
        SHER   81 
H – Isoniazid  E – Ethambutol 
T – Thioacetazone Z – Pyrazinamide 
P – PAS   R - Rifampicin     Table 2 summarises findings from bacterio- 
logically positive patients on Madras,3 East Afri-
ca2,4 and Hong Kong 5 and presents the bacteri-
cidal activity of various regimens measured in
terms of proportions of sputum-positive cases
who convert to negativity by the end of two
months of chemotherapy. Although  the data on
the H, TH, PH and EH regimens pertain to
regimens of conventional 12-months duration in
Madres, they are relevant for the present analy-
ses. The regimens of isoniazid alone in Madras
produced sputum conversion in 44% of patients,
an achievement reflecting the high bactericidal
potential of the drug. The addition of the bacte-
rioststic drug thioacetazone, PAS or ethambutol
to isoniazid did not result in any significant
increase of the bactericidal activity. The pro-
portion of 49% achieved in East Africa with the
two- drug combination, streptomycin plus iso-
niazid, is not much higher than what was achie-
ved with isoniazid alone in Madras, suggesting
that the contribution of streptomycin to the  
who have a bacteriological relapse later.   
Drug    Bactericidal activity  
 
  In vitro        In mouse      In guinea-
                Pig 
 
 
 
Isoniazid    2+                   2+              2+ 
 
Rifampicin    2+                   2+              2+ 
 
Streptomycin    3+                   1+**          2+ 
 
Pyrazinamide    2+*                 2+**           0** 
 *pH 5.2 – 5.6 
** Drug given in a dosage considerable higher than
that used in man 
       Two important indices are used to assess the
relativity efficacy of short-course regimens,
namely the speed with which the bacilli are 
 Killed, measured as the proportion of sputum-
positive cases who convert to negativity by the
end of two months of chemotherapy and the
ability to kill bacilli which have a tendency to
pesist during chemotherapy, measured as the
proportion of patients with quiescent disease 1 Ind. J. Tub., Vol. XXXIX, No. 
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 TABLE 3 
 Sterilising activity of persisting bacilli 2,5,6,8 
 
Regimen  
Duration of 
chemotherapy 
(months)  
Relapses 1-2 yrs 
after   stopping 
drugs (%)  
6SH*  
 
6SHT  
 
6SHZ 
 
6HR 
 
6 SHR  
 
2 SHRE/SHE2**  
 
2 SHRZ /SHZ2  
 
2 SHRE/SHE2  
 
2 SHRZ/SHZ2  
6  
 
6  
 
6  
 
6  
 
6  
 
6 
 
6 
  
            8 
 
            8  
29  
 
22  
 
8 
 
7  
 
   2 
23  
 
  7 
 
10 
 
3 
*The prefix indicates the number of months of che-
motherapy. 
 **The suffix indicates the number of doses of the drugs 
during the week 
the other hand, made a significant contribution, 
and reduced the relapse rate from 29% to 8%. 
The contrast between pyrazinamide and etham-
butol clearly shows that the sterilising activity 
of ethambutol is inferior to that of pyrazina-
mide. The low relapses associated with the 6 
HR and the 6 SHR regimens speak eloquently 
of the substantial and significant contribution 
of rifampicin in achieving sterilisation. 
The proportion, of patients with negative 
cultures at 2 months is only an indirect and 
partial evidence of the efficacy of the regimen. 
While a low proportion negative at 2 months 
indicates a low efficacy, a high proportion is no 
guarantee of a sterilising activity; the outcome 
would depend upon the potency of the drugs 
administered during the succeeding months. 
The proportion of patients who have relapses 
after the end of the scheduled course of chemo-
therapy provides a more direct and definite 
evidence of the sterilising activity of regimens. 
A critical review of the findings of several con-
trolled clinical trials would show that isoniazid, 
rifampicin, pyra2inamide and streptomycin are 
drugs with bactericidal and sterilising activity 
and can be employed in appropriate combina-
tions in short-course chemotherapy.9,10 Etha- 
mbutol, PAS and thioacetazone are largely 
bacteriostatic in action, and therefore have a 
limited role in short-course chemotherapy. 
Role of individual drugs in drug combinations 
Relapse rates associated with short-course 
regimens of varying durations and containing 
different combinations of drugs provide clues 
to the contribution of each drug to the overall 
efficacy of the regimens. 
It is generally accepted that isoniazid is the 
antituberculosis drug par excellence. Given 
alone in high dosage, isoniazid produces sputum 
conversion in about 70% of sputum-positive 
cases and most of those who convert remain free 
from relapse. Due to ethical considerations, the 
efficacy of isoniazid vis-a-vis any other anti-
tuberculosis drug cannot be investigated by 
conducting controlled clinical trials with regi-
mens with and without isoniazid; there is no 
such limitation in the case of other drugs. 
Many controlled clinical trials with short-course 
regimens have been designed with the aim of 
measuring the contribution of individual drugs. 
The findings from those trials lead to the follow-
ing conclusions. 
Pyrazinamide when added to combinations 
of SH or SHR makes a significant contribution 
to the sterilising activity of the regimens; the 
evidence clearly suggests that while the adminis-
tration of pyrazinamide during the first two 
months enhances the bactericidal activity of 
the regimen, its continued administration be-
yond 2 months does not confer any additional 
benefit. Rifampicin., similarly, makes a sub-
stantial and significant addition to the sterili-
sing activity of the combinations SH and 
SHZ but, unlike pyrazinamide, it continues to 
make an important contribution even during 
the continuation phase beyond two months. 
Streptomycin is a poor companion drug to 
isoniazid. While the addition of streptomycin 
to HRZ or HR reduces the relapse rates, the 
extent of reduction is small. 
In addition to the findings from the clinical 
trials, evidence from mouse experiments con-
ducted at the Pasteur Institute, Paris11, from 
In vivo and in vitro laboratory experimental 
work of Prof. Mitchison’s Unit in London12,13  
and from studies in East Africa14 on the reduc-   
tion in viable bacterial counts in sputum achiev 
ed with 2 days of chemotherapy have also provi-
ded valuable data on the activity of antituber-
culosis drugs. On the basis of these findings. 
Prof. Mitchison15 has suggested the existence of 
four types of bacterial populations according 
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to their anatomical location. The first is a popu-
lation of actively growing bacilli present in the 
liquefied caseous material. This is by far the 
largest fraction of the total bacterial population 
and contributes to the entire bulk of the bacilli 
excreted in the sputum, in untreated patients 
and in the early months of treatment. These  
bacilli are killed by isoniazid, and, to a smaller 
extent, by rifampicin and streptomycin. Even 
when administered alone, isoniazid can effecti-
vely eliminate nearly all of this population; the 
only bacilli which would survive are the small 
number of drug-resistant mutants. 
The second population consists of slow-
growing bacilli situated within the macrophages 
in an acidic milieu; they escape the action of all 
antituberculosis drugs except pyrazinamide and, 
to some extent, rifampicin. The third population 
consists of small number of bacilli which are 
present extra-cellularly in solid caseous lesions 
and exhibit brief spurts of metabolic activity; 
rifampicin is the only drug which acts rapidly 
and kills bacilli during the brief periods of 
activity. There is possibly a fourth population 
of dormant bacilli which are not killed by any 
drug. All these populations exist in the lesions 
and hence it is necessary to give at least 3 drugs 
—isoniazid, rifampicin and pyrazinamide, and 
possibly streptomycin as well, to ensure sterili-
sation of the lesion. 
Rhythm of administration of drugs 
In conventional chemotherapy, intermittent 
regimens have been shown to be highly effective. 
Intermittent regimens permit drugs to be admi-
nistered under full supervision so that concealed 
drug irregularity is eliminated; adverse reactions 
are generally less frequent with intermittent 
regimens than when the drugs are given daily, 
and finaliy, intermittent regimens are often less 
expensive. Intermittent regimens can also be 
employed in short-course chemotherapy. Thus, 
in one study in Hong Kong,16 a combination of 
SHZ administered for 9 months was equally 
effective when administered daily, three times 
a week or twice a week, the relapse rates being 
of the order of 5-6%. Many of the short-course 
regimens investigated in the past have applied 
the principle of intermittency in the continuation 
phase following an initial daily phase. Since 
regimens which are intermittent from the start 
of treatment would have practical advantages, 
studies should be undertaken to evolve effective 
fully intermittent regimens. 
Duration of chemotherapy 
A regimen of rifampicin plus isoniazid daily 
for 9 months, with an initial daily supplement 
of streptomycin or ethambutol during the first 
2 months, is associated with a 0% relapse rate 
during 2 years of follow-up and is now standard 
chemotherapy in technically advanced countries. 
Reviewing data from two BTA and two French 
controlled trials with 9 months of HR (with 
2 or 3 months of daily streptomycin initially), 
Fox10 observed that the 9-month regimens were 
highly effective, with only 3 (1 %) of 298 patients 
having had a relapse during a follow-up of 9-
45 months. Six month regimens of HR, how-
ever, have generally been associated with re-
lapses of up to 10%. The relapse rates, how-
ever, are substantially lower if pyrazinamide is 
administered in addition to 6 HR. Indeed, as 
already stated, pyrazinamide need be administer-
ed only for the first 2 months. A combination 
of SHRZ daily for 2 months is highly potent 
and renders approximately 95% of patients 
sputum-negative by 2 months, so that continu-
ation of chemotherapy with HR daily or SHZ 
twice a week for 4 months produces results as 
good as those attained with 9 months of HR. 
Examples of highly effective 6-7 month regimens 
are indicated in table 4. 
The first four regimens require daily adminis-
tration of drugs and hence it may be difficult to 
organise supervised chemotherapy on an ambu-
latory basis throughout the period of chemo-
therapy; the drugs may have to be self-adminis-
tered by the patient during the continuation 
phase. The next 4 require daily attendance for 
only 2 or 3 months, with twice-weekly chemo-
therapy thereafter. The last 2 regimens require 
only thrice a week chemotherapy, so that fully 
supervised chemotherapy can be easily orga-
nised. Regimens 2 EHRZ/HR and EHRZ3 are 
fully oral regimens so that they can be employed 
in rural areas where injection facilities may 
not be adequate. 
In summary, there is a wide variety of highly 
effective 5-7 month regimens which offer the 
physician opportunities to adapt the regimen 
to the need of a particular patient or to suit the 
infra-structure in the local health services. 
Table 5 gives examples of regimens of shorter 
durations, namely 3 or 4 months. These regi-
mens all have relatively higher relapses rates, 
namely, 8-16% for the 4-month regimens, and 
6-14% for the 3-month regimens. 
Although the relapse rates appear to be 
unacceptable, it should be appreciated that the 
overall results achieved with these regimens are 
still over 80%, and because of the short duration 
of chemotherapy, the likelihood of most patients 
completing their scheduled chemotherapy is 
very high. Conventional regimens of 12 months’ 
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TABLE 4  
Bacteriological relapses associated with highly effective 6-month regimens10,17-21 
-  
    
Regimen  Dura lion  Study  
 (months)   
  Bact. 
relapses  
(%)  
    
2 SHRZ/HR2 
2 SHRZ/HRZ  
2 EHRZ/HR 
3 SHRZ/RH 
2 SHRZ/SHZ2 
SHRZ/HR 3 
SHRZ/SH23  
           
          3 SHRZ/SHZ2  
SHRZ3 
EHRZ3  
 
6 
 
6  
 6 
5  
7  
6 
 5 
5  
6 
 6  
       Singapore/East Africa/U.K.  
      Singapore/ East Africa  
  U.K 
Agra 
Madras 
Poland 
Madras  
            
              Agra  
Hong Kong 
Hong Kong  
          0-2 
           0  
           1  
           2 
           0 
           0  
           3  
            2  
           1 
           2  
TABLE 5  
Bacteriological relapse rates : regimens of 3 or 4 month’ duration 
 
Regimen  
Duration 
(months)  
Study  Bact. 
relapses 
(%)  
2 SHRZ/RH(Z)  4  Singapore/East Africa  8— 16  
SHRZ  3  Madras/ Agra  6—14  
SHR  3  France  17  
 
 
 
duration such as PH or TH are associated with 
about 15% failures during chemotherapy in 
patients who have drug-sensitive cultures initia-
lly and have taken the drugs regularly, and an 
additional 15-20% have bacteriological relapses 
after stopping chemotherapy. Thus, the overall 
efficacy of such conventional regimens rarely 
exceeds 70% even under the best conditions, 
and often the results are much poorer under 
programme conditions. An overall success rate 
of over 80% achieved with the 3-month regimen 
 
is an acceptable alternative to the conventional 
regimen for developing countries. Indeed, the 
efficacy can be further improved by evolving 
a system by which patients are administered 3 
months of SHRZ under full supervision, and 
are then given a further 3-month supply of iso-
niazid to be self-administered by the patient 
daily at home. Assuming that only some of the 
patients take the continuation chemotherapy, 
the overall result would be a reduction in the 
relapse rate. 
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Regimens without rifampicin 
Pyrazinamide and rifampicin contribute to 
the bulk of the cost of short course regimens. 
Many developing countries with limited re-
sources would find it difficult to provide the large 
financial outlay necessary for employing rifam-
picin in mass treatment programmes. 
In a study conducted at Madras, a 7-
month non-rifampicin regimen of 2 SHZ/SHZ2 
was highly effective in patients having drug-
sensitive cultures initially, with a relapse rate of 
only 3%, and this regimen is therefore likely to 
be useful in developing countries if the level of 
initial drug-resistance is not high. The results 
of a study23 conducted by the Tuberculosis 
Association of India are of particular interest. 
A. 20-week regimen of SHER was found to be 
associated with a relapse rate (including bacterio-
logical and clinical relapses) of 16%, com-
pared with 32 % in patients treated with SHEZ, 
thus, the efficacy of the pyrazinamide regimen 
was substantially lower than that of the rif-
ampicin regimen, suggesting that regimens 
which do not contain rifampicin may have to 
be given for longer periods. It must, however, 
be emphasised that while non-rifampicin pyra-
zinamide regimens of 6 or 7 months duration 
can be formulated for application in situations 
where the level of initial drug resistance is not 
high, they are likely to be associated with failures 
in some patients with isoniazid resistance, and 
especially in those with resistance to both stre-
ptomycin and isoniazid. The use of regimens 
containing both pyrazinamide and rifampicin 
should be considered in all situations where 
the level of initial drug-resistance is high. 
Smear-negative  pulmonary tuberculosis 
In the Eighth Report of the WHO Tuber-
culosis Expert Group,24 a case of pulmonary 
tuberculosis was defined as one who was bacte-
riologically positive, and those who were bacte-
riologically negative were termed as “suspects”. 
To many this gave the impression that the 
World Health Organisation did not want the 
sputum-negative cases to be treated. This is far 
from the truth, as has been clarified in the Ninth 
Report.25 Smear-negative symptomatic patients 
with X-ray abnormality do need treatment and 
should be treated. Support for such a policy is 
provided by the conclusive evidence from a 
recent study on smear-negative pulmonary tuber-
culosis in Hong Kong.26,27 In this study, patients 
were randomly allocated to four series—the 
first, a selective chemotherapy series wherein 
patients were closely followed up by periodic 
bacteriological and X-ray examination and were 
given specific antituberculosis treatment only if 
they become culture-positive or, if there was 
radiographic or clinical deterioration. Two 
other groups were given short-course chemothe-
rapy with 4 drugs—SHRZ—daily for 2 or 3 
months (2 SHRZ, 3SHKZ). The fourth group 
of patients received a standard chemotherapy 
with daily streptomycin, PAS and isoniazid for 
3 months, followed by streptomycin and isonia-
zid twice a week (or, exceptionally, by isonia-
zid and PAS daily) for a further 9 months. This 
study clearly showed that as many as 71 % of 
283 patients in the Selective Chemotherapy 
series who were initially left untreated had 
chemotherapy started within 30 months be-
cause of confirmation of active disease, a find-
ing which underscores the necessity for treat-
ing such cases. 
Information on the efficacy of short-course 
regimens in smear-negative pulmonary tuber-
culosis is limited. Results of two such studies 10,27 
are summarised in Table 6. The top half of the 
table pertains to data on patients who had 
smear-negative culture-passive tuberculosis, and 
those in the lower section refer to patients with 
smear-negative and culture negative disease. 
Considering the culture-positive cases, the 
results clearly show that the 2-month regimen 
with a relapse rate of 28% was inadequate, and 
even the 3-month regimen was net a sterilising 
regimen. These results suggest that the behavi-
our of smear-negative culture-positive disease 
is not significantly different from that of smear-
positive culture-positive disease in respect of 
response to treatment. 
Considering patients with culture-negative 
disease, the relapse rates of 1-10% with the four 
drug regimens are substantially lower than 
the 56% break-down rate observed in the Selec-
tive Chemotherapy series, clearly indicating the 
beneficial effect of chemotherapy. It is, how-
ever, clear that the 2-month regimen was in-
adequate, and only the 4-month regimen was 
able to completely prevent the occurrence of 
relapses. 
Duration  of treatment in relation   to 
sputum results 
In the light of the findings discussed above, 
marginal adjustments can be made in the dura-
tion of chemotherapy according to the sputum 
smear and culture results. The optimum dura-
tions of chemotherapy for the various categories 
of patients are summarized in Table 7. 
The three categories of patients differ widely 
in their bacterial content. The smear-positive 
cases generally excrete millions of bacilli in their 
sputum each day, and constitute the greatest 
risk from the epidemiological stand-point. 
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TABLE 6 
Patients with smear-negative disease : Relapse rates in two Hong Kong studies 
 
 
 
Sm
Sm
cu
 
Sm
cu
C
m
c
n
p
w
s
th
n
tr 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sputum         Regimen and duration          Follow-up              Patients                 Bact.                  All 
culture                     (months)                     (months)               assessed             relapses              relapses
result                                     (%)           (%) 
 
  2 SHRZ   46  69  19  28 
 
  3 SHRZ   45  68  6  12 
 
Positive  4 SHRZ       8+  78  3  4 
   
  4 SHRZ3                   8+  63  0  0 
 
  6 SHRZ3       6+  81  0  2 
 
  2 SHRZ   46  154  6  10 
 
  3 SHRZ   45  154  2  5 
 
Negative 3 SHRZ3         9+  181  1  3 
 
4 SHRZ3       8+  146  0   1 
 
                    Selective Chemotherapy 48  171  42               56
          
TABLE   7 
Optimum duration of chemotherapy 
Sputum results  Optimum duration  
ear-positive  6 months  
ear-negative, 
lture-positive  
5 or 6 months  
 
ear-negative, 
lture-negative                
      4, 5 or   6   months 
ontacts of patients positive by sputum smear 
icroscopy run a much higher risk of infection 
ompared with contacts of patients with culture-
egative tuberculosis, and yet from the thera-
eutic point of view the culture-negative cases 
ith no demonstrable bacilli in their sputum 
eem to be requiring almost as much chemo-
erapy as the smear-positive cases. The expla-
ation for this paradox possibly lies in the dis-
ibution and nature of the bacilli in the three 
categories. The three categories of patients 
probably differ very little in their content of 
slowly multiplying bacteria (which alone deter-
mine the occurrence of relapse) and this common 
factor probably dictates the need for almost 
similar durations of treatment. 
Other low-cost regimens 
      Both rifampicin and pyrazinamide are 
expensive, and many developing countries may 
not be able to afford the regimens if both the 
drugs are prescribed for the total duration. One 
way of making the regimen relatively inexpen-
sive is by limiting the two drugs to the first two 
months only. Thus, a course of RSHZ daily for 
2 months may be followed by maintenance 
chemotherapy with an inexpensive combination 
—thioacetazone plus isoniazid (TH), which can 
be self-administered by the patient. Table 8 28 
summarises the results of a study in East Africa, 
employing such inexpensive regimens. 
It will be seen that the 6-month regimens are 
unsatisfactory and the duration of treatment 
should be increased to 8 months if TH is employ-
ed in the continuation phase. The three 8-
month regimens are all highly effective, the best 
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TABLE   8  
Low cost short-course regimens 
 
 Relapses (%)  
Regime n  
 6 month  8 month  
2 SHRZ/TH  12  0  
1   SHRZ/TH  19  7  
2 SHR/TH  18 6  
results being obtained with the regimen contain-
ing a 2-montb intensive phase with the 4 drugs, 
RSHZ. Reducing the duration of the intensive 
phase to 1 month or the number of drugs during 
this phase to three (i.e. excluding pyrazinamide) 
results in a slightly lower efficacy, with relapse 
rates of only 6 or 7%. Thus, ail the three in-
expensive regimens nave high and acceptable 
levels of over-all efficacy. In another study, 
results of continuation chemotherapy with iso-
niazid alone for 6 months (after 2 SHRZ) were 
highly encouraging, with about 1 % relapses 
during a 6-month follow-up. 
Regimens for high prevalence of initial resistance 
All the results presented in the earlier sections 
are based on patients infected with drug sensi-
tive cultures. Table 9 summarises findings on 
patients with initial drug-resistance admitted 
to two short-course studies in Madras18, 19 The 
data are presented separately for the rifampicin 
regimens (2 SHRZ/3 SHRZ2, 2 SHRZ/5 SHZ2, 
3 SHRZ, and 3 SHRZ/2 SH2) and non-rifam-
picin regimens (2 SHZ/5 SHZ2 and 3 SHZ/2 
SHZ3). 
It will be seen that streptomycin resistance 
was of no consequence. With the rifampicin 
regimes, resistance to isoniazid alone was of 
little consequence, and while 23 % failed in the 
presence of resistance to both the drugs, the 
over-all results were very encouraging, with a 
failure rate of only 12 %. The proportions of 
failure are substantially higher in the group of 
patients treated with the non-rifampicin regi-
mens- Indeed, this is one justification for 
employing the rifampicin regimens in prefer-
ence to those without, especially in countries 
where the level of initial drug-resistance is high. 
In such situations it might be prudent to add a 
fifth drug (ethambutol) during the initial inten-
sive phase while treating serious forms of tuber-
culosis such as tuberculous meningitis. 
 
Short-course chemotherapy for other forms of 
tuberculosis 
The efficacy of short-course regimens in 
pulmonary tuberculosis has been very clearly 
established in several controlled trials and in 
TABLE   9 
Patients with bacteriologically  positive disease and initial drug-resistance 
response to short-course regimens 
Rifampicin regimens  Non-rifampicin   regimens  
Resistance to :  
Patients 
assessed  
Failure 
during 
chemo-
therapy 
  (%)  
Relapses 
    (%)  
Patients 
assessed  
Failure 
during 
chemo-
therapy 
   (%)  
Relapses 
    (%) 
S  36  0  11  24  4  4  
H  68  7  6  33  36  14  
Both  69  23  6  42  74  0  
Any drug  173  12  8 99  44  7  
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diferent countries. There is, in contrast, very 
little information on the efficacy of such regi-
mens in extra-pulmonary tuberculosis such as 
meningitis, lymphadenitis and tuberculosis of 
the spine. Many trials in extra-pulmonary tuber-
culosis are in progress, and it is hoped that this 
lacuna will be filled. One can safely assume that 
regimens which have been found to be effective 
in pulmonary tuberculosis with very large bac-
terial populations will be at least as effective 
in extra-pulmonary tuberculosis with much 
smaller numbers of bacilli. However, the pro-
blem of the blood-brain barrier in tuberculous 
meningitis and the possible impairment of the 
immune mechanism in tuberculous lymphade-
enitis may require special consideration in the 
choice of drug-regimens. 
The choice of short-course regimens for Tuber-
culosis Programmes 
By now we have many short-course regimens, 
with a wide range of cost and high levels of 
efficacy. Not all of them, however, are suitable 
for application under programme conditions in 
developing countries where tuberculosis is a 
major public health programme. The follow-
ing are some of the important factors: 
(1) While an individual patient can be 
bestowed special attention, can be 
given more effective drugs, and can be 
monitored more frequently, such atten-
tion and care cannot be possible under 
mass chemotherapy under programme 
conditions. Treatment schedules for the 
programme should be simple and easy 
to operate and should not require too 
much of monitoring. 
(2) Cost: For most developing countries, 
cost of drugs is a major factor. There 
is a need to reduce the number of doses 
of pyrazinamide and rifampicin so that 
the regimen can be employed on a mass 
scale. The efficacy of the regimen may 
be compromised to some extent in the 
process, but this can be acceptable, pro 
vided the reduction   in efficacy is not 
large. 
(3) Level of success needed. This is a basic 
decision which must be taken, keeping 
the cost of the regimens and the financial 
resources in view.   Developing count- 
ries can ill-afford the 100% regimens 
used by technically advanced countries, 
employing rifampicin daily for 6 months 
or  9   months. The   conventional   12- 
month regimens achieve less than 60 % 
cure rate under programme conditions 
in these countries, and short-course 
regimens with cure rate of 80% or over 
would be attractive and acceptable 
under such conditions. To begin with, 
one should aim for realistic short-
course regimens, and when resources 
improve, one could aim to achieve the 
100% or near 100% level. 
(4) Facilities for injection:  In  developing 
countries, most patients reside in rural 
areas where injection facilities may be 
limited,   or   indeed   non-existent. The 
use of fully oral short-course regimens 
would be necessary in such a situation. 
(5) Fully-supervised or self-administered re- 
gimens: Again, in rural areas, it would 
be necessary to employ oral regimens 
capable of self-administration. In urban 
areas, however,   fully supervised  regi- 
mens   may   be   preferred. Thus,   the 
policy for the programme   should   be 
flexible and must take into considera 
tion local operational factors. 
(6) Toxicity: The possibility of occurrence 
of adverse reactions to the drugs and 
the possible potentiating effect of one 
drug on the incidence and severity of 
adverse reactions due to a companion 
drug need to be borne in mind. The 
concomitant use  of three  potentially 
hepatotoxic drugs, rifampicin, isoniazid 
and pyrazinamide may pose a problem 
in special groups such as alcoholics and 
in patients with possible hepatic involve 
ment in miliary tuberculosis. In general, 
intermittent regimens are likely to  be 
less often associated with adverse re 
actions  and  hence  may  be preferred 
to daily regimens. 
(7) Availability of the drugs:  One factor 
that  is  well  appreciated  is  the  non 
availability   of   adequate   and   timely 
supply   of  drugs.     Many   developing 
countries  depend  almost  entirely  on 
imports for their requirements of anti- 
tuberculosis drugs, and especially so for 
rifampicin   and    pyrazinamide.     This 
obviously poses limitations on the scale 
on which these drugs can be prescribed. 
Further, one must also take into consi 
deration logistics of transportation of 
drugs from central locations to remote 
rural areas where the bulk of the tuber 
culosis patients reside. 
It would be desirable that  all the above 
Ind. J. Tub., Vol. XXIX, No. 1 
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factors are taken into consideration while for-
mulating short-course regimens for the pro-
gramme. It is true that the short-course regi-
mens have not been tried under programme 
conditions, and hence there is a justification for 
studying their efficacy and applicability under 
programme conditions. It should, however, be 
appreciated that the results of such studies 
would not be available in the near future. It 
would be unfair to deny the tuberculosis patients 
the benefits of the bactericidal drugs pyrazina-
mide and rifampicin merely because they have 
not been investigated under programme con-
ditions. It is time that developing countries 
adopt short-course regimens for the progra-
me, but build in systems of monitoring the 
acceptability and efficacy into the programme. 
Provided it is agreed that the regimens can be 
modified at a later date in the light of experi-
ence gained in the early stages, there should be 
no objection to the introduction of appropriate 
short-course regimens in the National Tuber-
culosis Programme. 
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